Preliminary findings from the Phase II WSG‐KEYRICHED‐1 study also point to therapeutic potential when pembrolizumab is combined with dual HER2 blockade in HER2‐enriched early breast cancer [180]. The gene discussed is ERBB2; the disease is breast carcinoma.